Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Abdelghani Jebahi"'
Autor:
Frédéric Justaud, Hippolyte Paysant, Louis Bastien Weiswald, Abdelghani Jebahi, Marie Jouanne, Nicolas Elie, Anne Sophie Voisin-Chiret, Thierry Roisnel, Clément Orione, Nicolas Levoin, Laurent Poulain, René Grée
Publikováno v:
New Journal of Chemistry
New Journal of Chemistry, 2022, 46 (19), pp.9119-9127. ⟨10.1039/D1NJ05987D⟩
New Journal of Chemistry, 2022, 46 (19), pp.9119-9127. ⟨10.1039/D1NJ05987D⟩
International audience; The development of inhibitors of anti-apoptotic proteins, such as Mcl-1, is currently a very active area in the field of cancer research. One of the very first reported inhibitor of Mcl-1 was the molecule MIM1, but we have dem
Autor:
Charlène Duboc, Laurent Poulain, Marie-Hélène Louis, Edwige Abeilard, Marie Villedieu, Christophe Denoyelle, Pascal Gauduchon, Cécile Pétigny-Lechartier, Abdelghani Jebahi
Publikováno v:
Molecular Cancer Therapeutics. 16:102-115
The identification of novel therapeutic strategies is an important urgent requirement for the clinical management of ovarian cancer, which remains the leading cause of death from gynecologic cancer. Several studies have shown that the antiapoptotic p
Autor:
Laurent Poulain, Pascal Gauduchon, Abdelghani Jebahi, Emilie Brotin, Marie Villedieu, Marie-Hélène Louis, Cécile Pétigny-Lechartier, Florence Giffard, Mélanie Briand, Stephanie Lheureux, Marika Guercio, Edwige Abeilard
Publikováno v:
Cancer letters. 348(1-2)
We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis. Here we assessed the anticancer potential of combining ABT-737-induced inhibition of Bcl-xL with Mcl-1 inhibition via PI3K/Akt/mT
Autor:
Nicolas Aide, Florence Giffard, Mélanie Briand, Alain Batalla, Laurent Poulain, Stephanie Lheureux, Marie-Hélène Louis, Charlotte Lecerf, Cécile Blanc Fournier, Soizic Dutoit, Abdelghani Jebahi
Publikováno v:
Translational Oncology. 6:586-IN7
AIM: Targeting the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming chemoresistance in ovarian cancer. We investigated the capability of 18 F-fluororodeoxyglucose ( 18 F-FDG) small-anima